Press Kit: PBM Reality 2026 Editorial Review Pending
Dataset summary
- Scope: Three first-party OmniRx datasets cross-referenced: 53 drug-drug or drug-substance interactions, 55 patient assistance programs (PAPs), and 50 insurer or drug-coverage formulary records.
- Time range: Q2 2026 (April through June 2026), with PBM industry context drawn from the FTC's July 2024 and January 2025 interim staff reports.
- Geographic scope: United States. Insurer coverage includes UnitedHealthcare, BCBS, Aetna, Cigna, Humana, Kaiser, Anthem, Ambetter, Molina, Medicare Part D, TRICARE, Medicaid, VA, Marketplace, and Medicare Advantage.
- Method: First-party editorial audit. Severity grades follow DailyMed, FDA labeling, and PubMed-indexed pharmacology literature. PAP income limits normalized to %-FPL using 2025 HHS poverty guidelines. Formulary tier systems documented at the parent-insurer level.
- License: CC-BY 4.0; full dataset and aggregates available as machine-readable JSON.
- Lead author: Vincent, OmniRx Research. Editorial review by a credentialed clinician is pending.
Five quotable findings
"Forty-nine percent of the drug interactions we cataloged are graded Severe, and ibuprofen alone appears in nearly one in five of them. The interactions concentrate on a small set of high-prevalence medications, which is exactly where patient harm is most likely and where pharmacist counseling has the highest leverage."
Attribute to: Vincent, OmniRx Research, in OmniRx's 2026 PBM and Drug Coverage Cross-Reference. Editorial review pending.
"The modal patient assistance program in our database caps eligibility at 400 percent of the Federal Poverty Level, the same line the Affordable Care Act used for premium subsidies. That clustering is not coincidence. It tells you patient assistance programs are designed against visible regulatory thresholds, not against the actual distribution of patient need."
Attribute to: Vincent, OmniRx Research
"Sixty-six percent of patient assistance programs are run by the drug manufacturer, not by an independent nonprofit. A manufacturer PAP is a marketing-spend line item that covers only that manufacturer's portfolio. The patient ends up navigating a patchwork of brand-specific programs that the FTC's PBM reports describe at the wholesale layer and that we now document at the consumer-facing layer."
Attribute to: Vincent, OmniRx Research
"U.S. insurers run formularies on three different tier counts, plus closed formularies for VA and TRICARE. A patient comparing Aetna and UnitedHealthcare cannot map Tier 3 on one to Tier 3 on the other without translating through the tier-count difference. This structural opacity is the mechanism behind the same drug at the same wholesale cost producing different patient out-of-pocket prices across plans."
Attribute to: Vincent, OmniRx Research
"Twelve drugs sit at the intersection of clinical risk and PBM pricing variance, including insulin, metformin, lisinopril, sertraline, gabapentin, and Ozempic. These are the medications where polypharmacy compounds risk, formulary tiering compounds cost, and patient assistance programs only partially close the gap. The FTC's January 2025 second interim report singles out insulin specifically; our data shows it is one of twelve high-stakes drugs, not an outlier."
Attribute to: Vincent, OmniRx Research
Target outlets
KFF Health News (PBM and drug pricing beat); STAT News (Pharmalot, drug pricing investigations); ProPublica (health and prescription drug investigations); Bloomberg drug pricing desk; Healthcare Dive; Axios Vitals; the Drug Channels readership for industry context. Mark Cuban Cost Plus Drugs PR list welcome.
Headline numbers for editors
- 49.1% of cataloged drug interactions are Severe (26 of 53).
- 79.2% are Severe or Moderate combined (42 of 53).
- Ibuprofen is the most-flagged drug, appearing in 10 of 53 interactions (18.9%).
- 43.6% of PAPs cap eligibility at 400% FPL (24 of 55).
- 65.5% of PAPs are manufacturer-run (36 of 55).
- 3 different tier counts in use across major U.S. insurer formularies, plus closed formularies for VA and TRICARE.
- 12 drugs sit at the intersection of clinical risk and PBM pricing variance (48% of OmniRx drug-coverage records).
- 20% of OmniRx drug-coverage entries are GLP-1 or weight-loss drugs.
Downloads
- Full study (HTML): omnirx.org/research/pbm-spread-pricing-2026
- Open dataset (JSON): data.json [CC-BY 4.0]
- Methodology PDF: [PDF-PENDING] (available on request via media contact below)
- Full chart pack (PNG + SVG): [CHART-PACK-PENDING] (available on request)
- Source records: interactions, assistance, formulary
Republish & Embed the headline severity chart
Free to embed under CC-BY 4.0 with link attribution to the study page. The embedded chart includes the YMYL disclaimer banner; please do not strip it.
<iframe src="https://omnirx.org/research/pbm-spread-pricing-2026/embed/severity-distribution.html" width="100%" height="440" frameborder="0" loading="lazy" title="Drug interaction severity distribution across 53 OmniRx records, 2026"></iframe>CC-BY 4.0, please link to the source study when republishing. The embedded chart includes the disclaimer banner (not medical advice, severity grading pending clinical review); please do not strip it.
Primary sources cited in the study
- FTC Interim Staff Report on Pharmacy Benefit Managers (Jul 2024)
- FTC Second Interim Staff Report on Prescription Drug Middlemen (Jan 2025)
- openFDA Drug API
- FDA Adverse Event Reporting System (FAERS)
- CMS Medicare Part D Formulary Files
- GAO Report on PBMs (GAO-19-498)
- KFF Health System Tracker
- Mark Cuban Cost Plus Drug Company
- Drug Channels Institute (Adam Fein)
- NIH National Library of Medicine, DailyMed
Media contact
Vincent, OmniRx Research
Email: [email protected] [PRESS-EMAIL-PENDING]
Available for: written quotes (24 hour turnaround), data drill-down requests on any of the three datasets, on-record commentary on PBM structure, formulary tier opacity, patient assistance program design, and consumer-facing pharmacy navigation. We will route requests for clinical interpretation to a credentialed clinician once editorial review is finalized; for now, all clinical phrasing is conservative and editorial-review-pending.
Response time: typically same-day during ET business hours.
About OmniRx
OmniRx is an independent consumer pharmacy intelligence site at omnirx.org. We publish first-party drug interaction reference, formulary explainers, patient assistance program directories, and PBM industry research for U.S. patients. OmniRx is part of the DeepSynthesis Lattice, a constellation of niche research sites covering ecommerce, finance, education, and health verticals. We are not affiliated with any insurer, PBM, or pharmaceutical manufacturer.